Core Viewpoint - Guangji Pharmaceutical is facing financial pressure as it seeks large external financing while simultaneously reducing internal capital through a registered capital reduction of RMB 22 million for its wholly-owned subsidiary, Hubei Guangji Pharmaceutical Biotechnology Research Institute [1][3] Group 1: Capital Reduction and Strategic Planning - The company announced a reduction in registered capital for its subsidiary, decreasing it from RMB 50 million to RMB 28 million, aimed at optimizing asset structure and improving asset management efficiency [2][1] - The decision for capital reduction is based on the company's strategic planning and actual operational needs [2] Group 2: Financial Performance and Losses - Guangji Pharmaceutical reported a net loss of RMB 140 million in 2023, which is expected to increase to RMB 295 million in 2024, representing a year-on-year decline of 110.55% with total revenue dropping by 13.42% to RMB 639 million [4] - The company’s core product line, particularly the formulation series, has seen a significant decline, with revenue dropping by 65.26% in 2024 [4] - The financial structure has worsened, with total assets of RMB 2.58 billion and liabilities of RMB 1.62 billion, resulting in a debt-to-asset ratio of 62.67% as of Q3 2025 [5] Group 3: Regulatory Issues and Penalties - The company is also facing regulatory penalties due to information disclosure violations, resulting in a total fine of RMB 3.1 million imposed by the Hubei Securities Regulatory Bureau [6][7] - The violations involved misreporting revenue by using the gross method instead of the net method, leading to inflated revenue figures in multiple financial reports [7] Group 4: Future Outlook and Challenges - The company is attempting to enhance the competitiveness of its main products and improve asset management to reduce losses, but the path to recovery remains uncertain [7] - Questions remain regarding the specific use of funds from the capital reduction and whether the trend of reduced losses can be sustained moving forward [7]

Group 1 - The company held its 14th (temporary) meeting of the 11th Board of Directors on January 9, 2026, to discuss several key resolutions [1][4][61] - The board approved the repurchase and cancellation of 119,700 restricted stocks from five former employees who no longer meet the incentive conditions of the 2021 stock incentive plan [1][28][40] - The board also approved the nomination of Liu Wei as an independent director candidate, who will serve as the chair of the audit committee and a member of the remuneration and assessment committee [5][49] Group 2 - The board approved the revision and establishment of several governance systems to enhance operational standards and comply with relevant laws and regulations [8][53] - The company plans to reduce the registered capital of its wholly-owned subsidiary, Hubei Guangji Pharmaceutical Biotechnology Research Institute, by 22 million yuan, bringing the total registered capital down to 28 million yuan [55][59] - The company applied for a comprehensive credit line of 230 million yuan from Zheshang Bank, which includes a general credit limit of 130 million yuan and a low-risk credit limit of 100 million yuan [61][62] Group 3 - The company will hold its first temporary shareholders' meeting of 2026 on January 27, 2026, to discuss the approved resolutions [21][67] - The meeting will include both on-site and online voting options for shareholders [68][75] - The company ensures that all resolutions comply with the relevant laws and regulations, and the independent director candidate's qualifications will be subject to review by the Shenzhen Stock Exchange [50][71]

Group 1 - The company announced the approval of multiple resolutions during the 14th (temporary) meeting of the 11th Board of Directors, including the proposal to repurchase and cancel part of the restricted stock from the 2021 incentive plan [2] - The company also approved the proposal for the supplementary election of an independent director [2] - Additionally, the company passed resolutions to revise and establish certain governance systems [2]

Group 1 - The company Guangji Pharmaceutical (000952) announced that it will hold its first extraordinary general meeting of shareholders on January 27, 2026, at 15:30 [1]

Group 1 - The core point of the article is that Guangji Pharmaceutical (000952) has announced the nomination of Ms. Liu Wei as an independent director candidate for the 11th board of directors, along with her roles in various committees [1] Group 2 - Ms. Liu Wei will serve as the chairperson of the audit committee, a member of the remuneration and assessment committee, and a member of the budget management committee [1]

Core Viewpoint - Guangji Pharmaceutical (000952.SZ) announced a capital reduction for its wholly-owned subsidiary, the Biological Research Institute, from RMB 50 million to RMB 28 million, reflecting strategic planning and operational needs [1] Group 1: Capital Reduction Details - The registered capital of the Biological Research Institute will be reduced by RMB 22 million, resulting in a new registered capital of RMB 28 million [1] - As of the announcement date, the company has contributed RMB 24.5996 million in cash to the Biological Research Institute [1] - The company will maintain 100% ownership of the Biological Research Institute, ensuring no changes to the consolidated financial statements [1] Group 2: Authorization and Procedures - The company's board of directors has authorized relevant personnel to handle all matters related to the capital reduction, including determining the reduction plan and processing business registration changes [1]

Core Viewpoint - Guangji Pharmaceutical (000952.SZ) announced a capital reduction for its wholly-owned subsidiary, the Biological Research Institute, from RMB 50 million to RMB 28 million, reflecting strategic planning and operational needs [1] Group 1 - The registered capital of the Biological Research Institute was initially RMB 50 million, with a monetary contribution of RMB 24.5996 million made as of the announcement date [1] - The company plans to reduce the registered capital by RMB 22 million, resulting in a new registered capital of RMB 28 million, subject to final registration with the industrial and commercial authorities [1] - The company will maintain 100% ownership of the Biological Research Institute, ensuring that the consolidation scope of the company's financial statements remains unchanged [1] Group 2 - The board of directors has authorized relevant personnel to handle all matters related to this capital reduction, including determining the reduction plan and processing the necessary changes with the industrial and commercial authorities [1]

证券代码：000952 证券简称：广济药业 公告编号：2026-005 湖北广济药业股份有限公司 关于对全资子公司减资的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假记载、误 导性陈述或重大遗漏。 湖北广济药业股份有限公司（以下简称"公司"）于 2026 年 1 月 9 日召 开第十一届董事会第十四次（临时）会议，审议通过了《关于对全资子公司减 资的议案》，同意对公司全资子公司湖北广济药业生物技术研究院有限公司 （以下简称"生物研究院"）减少注册资本人民币 2,200 万元。相关情况公告 如下： 1.公司名称：湖北广济药业生物技术研究院有限公司 2.企业类型：有限责任公司（非自然人投资或控股的法人独资） 3.统一社会信用代码：91420100MA49JEFMX4 4.住所：武汉东湖新技术开发区高新二路 388 号武汉光谷国际生物医药企 业加速器 3.2 期 11 号厂房 1-6 层 01 号（自贸区武汉片区） 5.法定代表人：方智 6.注册资本：伍仟万圆人民币 一、本次减资概况 公司全资子公司生物研究院注册资本为人民币 5,000 万元，截至公告披露 日，通过货币出资 2,459.9 ...

证券代码：000952 证券简称：广济药业 公告编号：2026-002 湖北广济药业股份有限公司 关于回购注销 2021 年限制性股票激励计划 部分限制性股票的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误 导性陈述或重大遗漏。 特别提示： 1、本次拟回购注销限制性股票数量为 11.97 万股，约占回购注销前公司股 本总额的 0.03%。 2、本次拟回购注销限制性股票的回购金额合计 421,344 元，回购资金来源 为公司自有资金。 3、本次注销完成后，公司总股本将由 346,750,339 股减少至 346,630,639 股。 湖北广济药业股份有限公司（以下简称"广济药业"或"公司"）于 2026 年 1 月 9 日召开第十一届董事会第十四次（临时）会议，审议通过了《关于回购 注销 2021 年限制性股票激励计划部分限制性股票的议案》。现将有关事项公告 如下： 一、公司 2021 年限制性股票激励计划（以下简称"本激励计划"）已履行 的决策程序和信息披露情况 （一）2021 年 11 月 12 日，公司召开第十届董事会第十次（临时）会议审 议通过了《关于〈湖北广济药业股份 ...

湖北广济药业股份有限公司 浙江佰事诚律师事务所 关于 回购注销 2021 年限制性股票激励计划 部分限制性股票 之 法律意见书 浙江佰事诚律师事务所 二零二六年一月 1 浙江佰事诚律师事务所 湖北广济药业股份有限公司： 浙江佰事诚律师事务所（以下简称"本所"）接受湖北广济药业股份 有限公司（以下简称"公司"或"广济药业"）的委托，就公司依据《上 市公司股权激励管理办法》（以下简称"《管理办法》"）等相关法律、 法规、规范性文件及《湖北广济药业股份有限公司 2021 年限制性股票激 励计划》（以下简称"《激励计划》"或"本次激励计划"）回购注销部 分激励对象已获授但尚未解除限售的限制性股票相关事宜（以下简称"本 次回购注销"）出具本法律意见。 对本法律意见书，本所律师声明如下： （一）本所律师依据《中华人民共和国证券法》《律师事务所从事证 券法律业务管理办法》和《律师事务所证券法律业务执业规则（试行）》 等规定及本法律意见书出具日以前已经发生或者存在的事实，严格履行了 法定职责，遵循了勤勉尽责和诚实信用原则，进行了充分的核查验证，保 证本法律意见所认定的事实真实、准确、完整，所发表的结论性意见合法、 准确，不存 ...